Publications

Refractory haematological malignancies carry poor prognoses when standard therapies fail. Ex-vivo drug sensitivity testing offers a functional approach to personalize salvage regimens. Clinicians at the University of Malaya evaluated the Optim.AI™ precision oncology platform in five heavily pretreated patients with refractory blood cancers. The cohort included cases of Burkitt lymphoma, B-cell acute lymphoblastic leukemia (B-ALL), […]

Functional Precision Medicine in Pancreatic Cancer Advanced pancreatic cancer still relies on empirically chosen drug combinations, and these yield response rates of only 20 to 40%. KRAS mutations in pancreatic cancer occur in over 90% of cases, yet responses to KRAS-targeted therapies vary. Functional precision medicine for pancreatic cancer tackles this problem by testing which […]

Introduction Treating heavily pretreated metastatic breast cancer presents a profound clinical challenge. Clinicians frequently lack predictive biomarkers for cytotoxic drug responses. Consequently, they must select subsequent lines of therapy empirically, which often yields modest clinical benefits. This issue becomes particularly acute in Triple Negative Breast Cancer (TNBC). Standard genomic-guided approaches regularly fail to identify actionable […]

The landscape of cancer treatment has shifted significantly with the rise of immunotherapies. However, response variability and a lack of reliable predictive biomarkers often limit their clinical impact. A recent study presented at AACR 2026 highlights a potential solution: Optim.AI™ 2.0. This co-culture, high-content functional precision platform is designed for predicting combinatorial immunotherapy response. Evolution […]

The prognosis for pancreatic cancer remains a significant clinical challenge, with a five-year survival rate of less than 10%. Standard treatments primarily involve chemotherapy, yet targeted therapies and immunotherapies remain limited to specific patient subsets. Currently, treatment selection is often empirical because of a lack of reliable predictive biomarkers. Combinatorial functional precision medicine offers a […]

Functional precision medicine has evolved significantly as a strategy to individualize treatment for patients with limited options. While ex vivo drug sensitivity testing has existed for decades, historical adoption was hindered by sample scarcity and inconsistent clinical correlation. However, recent real-world evidence of Optim.AI™ demonstrates a paradigm shift in managing hematological malignancies, particularly in complex […]

Standard care for gynecological malignancies, particularly ovarian and endometrial cancers, often involves platinum-based chemotherapy. While genetic testing for BRCA mutations or homologous recombination deficiency (HRD) can guide the use of PARP inhibitors, these actionable markers are only present in a subset of patients. This leaves a significant clinical gap for those with HRD-negative status or […]

KRAS mutations drive over 90% of pancreatic ductal adenocarcinoma (PDAC) cases. While inhibitors for $G12C$ mutations are FDA-approved, they benefit only 1% of patients. Most patients harbor $G12D$, $G12V$, or $G12R$ mutations, requiring broader therapeutic strategies. Recent research presented at AACR RAS 2026 highlights the Optim.AI™ platform. This functional precision medicine tool identifies effective drug […]

Bortezomib in Soft Tissue Sarcoma: Insights via Functional Testing Advanced Soft Tissue Sarcomas (STS) are rare, diverse tumors with limited treatment pathways. Standard first-line anthracyclines yield only a 20–30% response rate, and genetic markers rarely guide therapy. Functional precision medicine offers a solution by testing live tumor response to identify effective combination therapy. Bortezomib Repurposing […]

Functional Precision Medicine: Combinatorial Immunotherapy via Optim.AI™ 2.0 Current cancer care faces significant challenges due to response variability and a lack of predictive biomarkers for immunotherapy. To address this, the Optim.AI™ 2.0 platform integrates high-content imaging with ex vivo tumor-immune co-cultures to predict patient-specific responses to drug combinations. Methodology: High-Content Screening The platform utilizes primary […]